On the other hand, there was no statistically significant difference in the expression levels of CD80 and CD86 in cultures with abatacept compared with mock cultures, while there was a trend toward downregulation of CD80 and CD86 after abatacept exposure in RA monocytes (P = 0.13 and 0.09, respectively). This evidence concerns the gene CD86 and rheumatoid arthritis.